Cyprotex PLC Launch of Short Time Exposure Service
March 19 2015 - 3:02AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
19 March 2015
19(th) March 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex launch Short Time Exposure service for identifying
potential serious eye damage for new chemicals
Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research
Organisation (CRO), announce the launch of a new in vitro testing
service, the Short Time Exposure (STE) assay for identifying
potential serious eye damage from new chemicals. Cyprotex has
validated and demonstrated proficiency in the assay based on the
draft OECD (Organisation for Economic Co-operation and Development)
test guideline released in June 2014.
A complete ban on animal testing of all new cosmetics and their
ingredients sold in Europe was put into force in March 2013. In
addition, the Classification, Labelling and Packaging (CLP)
Regulation, the GHS (Global Harmonised System of Classification and
Labelling of Chemicals) and the REACH Regulation all propose the
use of in vitro alternative methods for toxicity testing. The STE
method has been developed as an in vitro(non-animal) alternative to
the animal-based rabbit eye test and Cyprotex are able to perform
the service under GLP (Good Laboratory Practice) in order to meet
the requirements of these regulatory bodies.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer said, "The
addition of the new STE service enables Cyprotex to test chemicals
for potentially harmful ocular effects. By bringing this on board
we comply with new regulatory guidance and are well placed to meet
the needs of our customers for non-animal alternative testing."
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1000 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFDPFDESEFF
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024